What is Teladoc Health, Inc.'s earnings per share (EPS)?

Teladoc Health, Inc. (TDOC) reported diluted earnings per share of -$1.14 for fiscal year 2025. This represents a 80.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Teladoc Health, Inc. (TDOC) Financials

TDOC

Trailing 12 months to June 30, 2026

Revenue $2.5B -2.1% YoY

Net Income -$177.4M +14.4% YoY

EPS (Diluted) -$0.99 +15.4% YoY

Free Cash Flow $253.7M -13.0% YoY

Market Cap $1.1B as of Oct 14, 2026

Price / Sales 0.4x on $2.5B revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book 0.8x on $1.3B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 30, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 30, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TDOC SEC filings page.

Teladoc Health, Inc. (TDOC) reported $2.5B in revenue over the twelve months to Jun 30, 2026, down 2.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TDOC FY2025 2026-10-03

Teladoc’s core economics remain high-margin, but shrinking revenue still has not translated into operating profitability.

FY2025 paired a net loss of $200M with operating cash flow of $294M, so reported losses did not represent an equivalent cash drain. Free cash flow stayed close to operating cash flow, indicating the business currently requires relatively little fixed-asset reinvestment; the gap is therefore more about noncash accounting costs than capital spending.

Revenue remained below FY2023 while gross margin held near 70.0%; that combination says the main pressure is not basic service-delivery economics alone. FY2025’s operating recovery was cost-led: revenue declined while SG&A and R&D both fell, moving operating margin to -10.4% from FY2024’s much weaker level without reaching break-even.

FY2025’s current ratio of 2.8x and debt-to-equity of 1.1x point to better short-term coverage than the prior year. Yet equity fell from $2.3B in FY2023 to $1.4B in FY2025, so improved liquidity does not mean the capital base has strengthened.

Financial Health Signals

Financial Health Score 41/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Teladoc Health, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Teladoc Health, Inc. has an operating margin of -10.4%, meaning the company loses $10 on every $100 of revenue. This results in a profitability score of 15/100. This is up from -39.7% the prior year.

Growth

Teladoc Health, Inc.'s revenue declined 1.5% year-over-year, from $2.6B to $2.5B. This contraction results in a growth score of 26/100.

Leverage

Teladoc Health, Inc. has a moderate D/E ratio of 1.06. This balance of debt and equity financing earns a leverage score of 46/100.

Liquidity

With a current ratio of 2.77, Teladoc Health, Inc. holds $2.77 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 75/100.

Cash Flow

Teladoc Health, Inc. converts 11.3% of revenue into free cash flow ($285.5M). This strong cash generation earns a score of 70/100.

Returns

Teladoc Health, Inc. posts a -14.5% return on equity (ROE), meaning it loses $14 for every $100 of shareholders' equity. This results in a returns score of 15/100. This is up from -67.2% the prior year.

Altman Z-Score Distress

-6.72

Teladoc Health, Inc. scores -6.72, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($1.1B) relative to total liabilities ($1.5B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

5/8

Teladoc Health, Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

N/A

Teladoc Health, Inc. reported a net loss of $200.3M while generating $294.4M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Teladoc Health, Inc. reported an operating loss of $263.0M against $19.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$606.9M

YoY-4.0%

QoQ-1.1%

5Y CAGR+3.8%

10Y CAGR+36.8%

Teladoc Health, Inc. generated $606.9M in revenue in Q2 2026. This represents a decrease of 4.0% from the same quarter a year earlier. Against the prior quarter it is down 1.1%.

Net Income

-$38.9M

YoY-19.1%

QoQ+39.1%

Teladoc Health, Inc. reported -$38.9M in net income in Q2 2026. This represents a decrease of 19.1% from the same quarter a year earlier. Against the prior quarter it is up 39.1%.

EPS (Diluted)

-$0.21

YoY-10.5%

QoQ+41.7%

Teladoc Health, Inc. earned -$0.21 per diluted share (EPS) in Q2 2026. This represents a decrease of 10.5% from the same quarter a year earlier. Against the prior quarter it is up 41.7%.

EBITDA

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

$63.7M

YoY-29.3%

QoQ+711.3%

5Y CAGR+5.0%

Teladoc Health, Inc. generated $63.7M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 29.3% from the same quarter a year earlier. Against the prior quarter it is up 711.3%.

Cash & Debt

$774.3M

YoY+13.9%

QoQ+3.1%

5Y CAGR-0.2%

10Y CAGR+30.1%

Teladoc Health, Inc. held $774.3M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

182M

YoY+2.8%

QoQ+0.6%

5Y CAGR+2.7%

10Y CAGR+14.8%

Teladoc Health, Inc. had 182M shares outstanding in Q2 2026. This represents an increase of 2.8% from the same quarter a year earlier. Against the prior quarter it is up 0.6%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

68.6%

YoY-1.3pp

QoQ+0.7pp

5Y change+0.4pp

10Y change-5.4pp

Teladoc Health, Inc.'s gross margin was 68.6% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.7 percentage points.

Operating Margin

-6.1%

YoY+2.5pp

QoQ+3.9pp

5Y change+9.6pp

10Y change+48.5pp

Teladoc Health, Inc.'s operating margin was -6.1% in Q2 2026, reflecting core business profitability. This is up 2.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.9 percentage points.

Net Margin

-6.4%

YoY-1.2pp

QoQ+4.0pp

5Y change+20.2pp

10Y change+49.8pp

Teladoc Health, Inc.'s net profit margin was -6.4% in Q2 2026, showing the share of revenue converted to profit. This is down 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.0 percentage points.

Return on Equity

-3.0%

YoY-0.7pp

QoQ+1.8pp

5Y change-2.1pp

10Y change+6.8pp

Teladoc Health, Inc.'s ROE was -3.0% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.8 percentage points.

Capital Allocation

R&D Spending

$62.9M

YoY-8.6%

QoQ-7.4%

5Y CAGR-4.9%

10Y CAGR+29.3%

Teladoc Health, Inc. invested $62.9M in research and development in Q2 2026. This represents a decrease of 8.6% from the same quarter a year earlier. Against the prior quarter it is down 7.4%.

Capital Expenditures

$928K

YoY-26.8%

QoQ-44.1%

5Y CAGR-16.5%

10Y CAGR+6.3%

Teladoc Health, Inc. invested $928K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 26.8% from the same quarter a year earlier. Against the prior quarter it is down 44.1%.

Share Buybacks

Not reported for Q2 2026.

TDOC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TDOC quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Revenue	$2.5B	$2.5B-1.5%	$2.6B-1.3%	$2.6B+8.1%	$2.4B+18.4%	$2.0B+85.8%	$1.1B+97.7%	$553.3M+32.4%	$417.9M+79.1%	$233.3M+89.4%	$123.2M+59.2%	$77.4M+77.8%	$43.5M+118.7%	$19.9M
Cost of Revenue	$772.6M	$771.6M+2.7%	$751.3M-1.2%	$760.0M+2.2%	$744.0M+14.4%	$650.3M+66.4%	$390.8M+111.9%	$184.5M+43.3%	$128.7M+108.9%	$61.6M+92.7%	$32.0M+51.9%	$21.0M+111.9%	$9.9M+137.2%	$4.2M
Gross Profit	$1.7B	$1.8B-3.3%	$1.8B-1.3%	$1.8B+10.8%	$1.7B+20.3%	$1.4B+96.6%	$703.1M+90.6%	$368.8M+27.6%	$289.2M+68.5%	$171.7M+88.2%	$91.2M+61.8%	$56.3M+67.7%	$33.6M+113.7%	$15.7M
R&D Expenses	$269.9M	$277.9M-9.6%	$307.3M-11.8%	$348.5M+4.5%	$333.6M+7.0%	$311.9M+89.1%	$164.9M+155.2%	$64.6M+18.9%	$54.4M+57.8%	$34.5M+58.0%	$21.8M+53.5%	$14.2M+87.6%	$7.6M+114.4%	$3.5M
SG&A Expenses	$417.1M	$431.9M-0.8%	$435.5M-6.3%	$464.7M+3.3%	$449.9M+2.7%	$438.0M-13.6%	$506.7M+208.1%	$164.5M+40.7%	$116.9M+46.5%	$79.8M+64.3%	$48.6M+13.0%	$43.0M+143.0%	$17.7M+101.6%	$8.8M
Operating Income	-$186.8M	-$263.0M+74.2%	-$1.0B-310.7%	-$248.6M+98.2%	-$13.7B-5039.9%	-$265.6M+47.5%	-$506.4M-529.5%	-$80.4M-13.5%	-$70.9M+6.0%	-$75.4M-20.3%	-$62.7M-12.3%	-$55.8M-268.2%	-$15.2M-158.1%	-$5.9M
EBITDA	N/A	N/A	N/A	N/A	-$13.4B-21722.4%	-$61.4M+85.9%	-$436.9M-953.1%	-$41.5M-17.7%	-$35.3M+37.4%	-$56.3M-3.5%	-$54.4M-6.8%	-$50.9M-296.9%	-$12.8M-150.8%	-$5.1M
Interest Expense	$20.0M	$19.7M-17.2%	$23.8M+6.8%	$22.3M+1.5%	$21.9M-73.0%	$81.1M+235.3%	-$60.0M-104.2%	-$29.4M-12.4%	-$26.1M-49.3%	-$17.5M-575.9%	-$2.6M-17.7%	-$2.2M-46.7%	-$1.5M-2576.8%	-$56K
Income Tax	-$5.2M	-$35.2M-563.8%	$7.6M+898.9%	$760K+119.9%	-$3.8M-108.6%	$44.1M+148.6%	-$90.9M-757.9%	-$10.6M-9075.4%	$118K+152.4%	-$225K-144.1%	$510K+1316.7%	$36K-90.7%	$388K+312.8%	$94K
Net Income	-$177.4M	-$200.3M+80.0%	-$1.0B-354.4%	-$220.4M+98.4%	-$13.7B-3085.6%	-$428.8M+11.6%	-$485.1M-390.7%	-$98.9M-1.8%	-$97.1M+9.1%	-$106.8M-43.9%	-$74.2M-27.9%	-$58.0M-240.6%	-$17.0M-183.1%	-$6.0M
EPS (Basic)	N/A	-$1.14+80.6%	-$5.87-338.1%	-$1.34+98.4%	-$84.60-2998.9%	-$2.73+49.1%	-$5.36-288.4%	-$1.38	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.99	-$1.14+80.6%	-$5.87-338.1%	-$1.34+98.4%	-$84.60-2998.9%	-$2.73	-$5.36	-$1.38	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	176M+3.3%	171M+3.6%	165M+1.9%	161M+2.9%	157M	91M	72M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$606.9M-4.0%	$613.8M-2.5%	$642.3M+0.3%	$626.4M-2.2%	$631.9M-1.6%	$629.4M-2.6%	$640.5M-3.0%	$640.5M-3.0%
Cost of Revenue	$190.8M+0.2%	$197.5M+0.4%	$197.0M+4.3%	$187.2M+4.1%	$190.5M+1.3%	$196.8M+1.2%	$188.9M-2.3%	$179.7M-3.3%
Gross Profit	$416.1M-5.7%	$416.3M-3.8%	$445.2M-1.4%	$439.3M-4.7%	$441.4M-2.9%	$432.5M-4.2%	$451.6M-3.3%	$460.8M-2.8%
R&D Expenses	$62.9M-8.6%	$67.9M-3.0%	$71.6M-6.7%	$67.6M-6.6%	$68.8M-10.4%	$70.0M-14.0%	$76.8M-14.7%	$72.4M-14.1%
SG&A Expenses	$104.0M-3.8%	$102.1M-9.5%	$108.4M+8.4%	$102.6M-10.2%	$108.1M-1.3%	$112.8M+1.0%	$100.0M-8.2%	$114.2M-1.3%
Operating Income	-$37.1M+31.8%	-$61.8M+48.8%	-$36.0M+25.3%	-$52.0M-17.0%	-$54.4M+93.5%	-$120.6M-38.4%	-$48.2M-37.4%	-$44.4M+31.4%
Interest Expense	$5.1M+14.2%	$5.4M-6.9%	$5.0M-27.7%	$4.5M-20.0%	$4.5M-20.8%	$5.8M+2.1%	$6.8M+23.6%	$5.7M+0.2%
Income Tax	$997K+112.8%	$3.0M+116.4%	-$8.5M-3660.9%	-$715K-191.7%	-$7.8M-299.9%	-$18.3M-778.6%	$238K-93.2%	$780K+131.4%
Net Income	-$38.9M-19.1%	-$63.8M+31.4%	-$25.1M+48.1%	-$49.5M-48.8%	-$32.7M+96.1%	-$93.0M-13.6%	-$48.4M-67.6%	-$33.3M+41.7%
EPS (Basic)	-$0.21-10.5%	-$0.36+32.1%	-$0.14+46.2%	-$0.28-47.4%	-$0.19+96.1%	-$0.53-8.2%	-$0.26-52.9%	-$0.19+45.7%
EPS (Diluted)	-$0.21-10.5%	-$0.36+32.1%	-$0.14+46.2%	-$0.28-47.4%	-$0.19+96.1%	-$0.53-8.2%	-$0.26-52.9%	-$0.19+45.7%
Diluted Shares (Avg)	181M+2.9%	179M+2.9%	N/A	177M+3.2%	176M+3.3%	174M+3.8%	N/A	171M+3.9%

Not reported in any period shown, so not listed: EBITDA.

TDOC Balance Sheet

TDOC quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$2.9B-18.7%	$3.5B-19.9%	$4.4B+1.1%	$4.3B-75.5%	$17.7B-0.1%	$17.8B+1007.7%	$1.6B+4.8%	$1.5B+85.5%	$824.4M+171.5%	$303.7M+32.2%	$229.7M+150.2%	$91.8M	N/A
Current Assets	$1.1B-32.7%	$1.7B+11.7%	$1.5B+13.2%	$1.3B+7.3%	$1.2B+15.7%	$1.1B+80.2%	$588.0M+10.4%	$532.7M+241.0%	$156.2M+88.9%	$82.7M-45.4%	$151.6M+178.2%	$54.5M	N/A
Cash & Equivalents	$781.1M-39.8%	$1.3B+15.5%	$1.1B+22.4%	$918.2M+2.8%	$893.5M+21.8%	$733.3M+42.6%	$514.4M+21.3%	$424.0M+890.2%	$42.8M-14.4%	$50.0M-9.2%	$55.1M+18.6%	$46.4M+1345.7%	$3.2M
Short-Term Investments	$0	$0	$0	$0-100.0%	$2.5M-95.2%	$53.2M+1864.0%	$2.7M-95.0%	$54.5M-31.4%	$79.5M+403.3%	$15.8M-80.8%	$82.3M	$0	$0
Inventory	$38.2M+0.2%	$38.1M+29.2%	$29.5M-47.6%	$56.3M-22.9%	$73.1M+29.3%	$56.5M	$0	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$192.8M-10.0%	$214.1M-1.5%	$217.4M+3.3%	$210.6M+24.6%	$169.0M-0.2%	$169.3M+197.3%	$56.9M+30.7%	$43.6M+60.8%	$27.1M+96.2%	$13.8M+13.8%	$12.1M+77.4%	$6.8M	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$283.2M0.0%	$283.2M-73.6%	$1.1B0.0%	$1.1B-92.6%	$14.5B-0.5%	$14.6B+1854.4%	$746.1M+1.2%	$737.2M+47.9%	$498.5M+164.9%	$188.2M+234.0%	$56.3M+98.0%	$28.5M+92.4%	$14.8M
Total Liabilities	$1.5B-27.3%	$2.0B-2.0%	$2.1B+1.4%	$2.0B+20.7%	$1.7B-9.8%	$1.9B+217.8%	$588.8M+14.2%	$515.8M+94.3%	$265.5M+264.7%	$72.8M+42.3%	$51.2M-67.9%	$159.4M	N/A
Current Liabilities	$404.7M-57.0%	$941.5M+123.8%	$420.6M+5.2%	$399.8M+20.8%	$331.0M-0.5%	$332.6M+268.9%	$90.2M+44.4%	$62.4M+54.8%	$40.3M+91.4%	$21.1M+17.2%	$18.0M+74.3%	$10.3M	N/A
Non-Current Liabilities	$1.1B-1.5%	$1.1B-34.1%	$1.6B+0.5%	$1.6B+20.6%	$1.4B-11.8%	$1.5B+208.6%	$498.6M+10.0%	$453.3M+101.3%	$225.2M+335.3%	$51.7M+55.9%	$33.2M-77.7%	$149.1M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$42.4M+68.2%	$25.2M+0.7%	$25.0M	N/A
Total Equity	$1.4B-7.1%	$1.5B-35.9%	$2.3B+0.8%	$2.3B-85.6%	$16.0B+1.0%	$15.9B+1466.4%	$1.0B+0.1%	$1.0B+81.3%	$558.9M+142.1%	$230.9M+29.3%	$178.6M+364.4%	-$67.5M-21.8%	-$55.5M
Retained Earnings	-$16.4B-1.2%	-$16.2B-6.6%	-$15.2B-1.5%	-$15.0B-955.8%	-$1.4B-43.2%	-$992.7M-95.6%	-$507.5M-24.2%	-$408.7M-31.2%	-$311.6M-52.2%	-$204.7M-56.9%	-$130.5M-80.0%	-$72.5M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$2.8B-4.7%	$2.8B-18.5%	$2.9B-18.7%	$2.9B-18.4%	$2.9B-17.9%	$3.4B-20.3%	$3.5B-19.9%	$3.5B-18.5%
Current Assets	$1.1B+7.0%	$1.1B-29.3%	$1.1B-32.7%	$1.1B-32.1%	$1.1B-30.6%	$1.6B+7.8%	$1.7B+11.7%	$1.6B+16.0%
Cash & Equivalents	$774.3M+13.9%	$750.7M-37.1%	$781.1M-39.8%	$726.2M-41.6%	$679.6M-41.5%	$1.2B+8.7%	$1.3B+15.5%	$1.2B+20.7%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$28.8M-24.5%	$31.6M-17.0%	$38.2M+0.2%	$39.9M+7.9%	$38.2M+9.4%	$38.0M+17.8%	$38.1M+29.2%	$37.0M+3.0%
Accounts Receivable	$221.0M-2.0%	$213.6M-8.3%	$192.8M-10.0%	$210.8M-0.6%	$225.4M+3.2%	$233.0M+8.7%	$214.1M-1.5%	$212.0M+3.0%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$283.2M0.0%	$283.2M0.0%	$283.2M0.0%	$283.2M0.0%	$283.2M0.0%	$283.2M-73.6%	$283.2M-73.6%	$283.2M-73.6%
Total Liabilities	$1.4B-1.6%	$1.5B-27.1%	$1.5B-27.3%	$1.5B-26.4%	$1.5B-27.2%	$2.0B-0.7%	$2.0B-2.0%	$2.0B-0.6%
Current Liabilities	$1.4B+243.9%	$404.9M-57.5%	$404.7M-57.0%	$405.1M-56.5%	$401.8M-56.8%	$952.4M+144.9%	$941.5M+123.8%	$931.4M+131.3%
Non-Current Liabilities	$66.8M-93.8%	$1.1B+0.1%	$1.1B-1.5%	$1.1B-0.7%	$1.1B-1.9%	$1.1B-35.2%	$1.1B-34.1%	$1.1B-33.2%
Total Equity	$1.3B-7.9%	$1.3B-6.4%	$1.4B-7.1%	$1.4B-7.7%	$1.4B-5.3%	$1.4B-37.7%	$1.5B-35.9%	$1.5B-34.3%
Retained Earnings	-$16.5B-1.1%	-$16.5B-1.0%	-$16.4B-1.2%	-$16.4B-1.4%	-$16.4B-1.3%	-$16.3B-6.6%	-$16.2B-6.6%	-$16.2B-6.5%

Not reported in any period shown, so not listed: Long-Term Debt.

TDOC Cash Flow Statement

TDOC quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	$261.2M	$294.4M+0.2%	$293.7M-16.1%	$350.0M+84.9%	$189.3M-2.4%	$194.0M+462.5%	-$53.5M-279.2%	$29.9M+714.6%	-$4.9M+85.9%	-$34.4M+33.6%	-$51.9M-9.9%	-$47.2M-315.4%	-$11.4M-87.7%	-$6.1M
Depreciation & Amortization	N/A	N/A	N/A	N/A	$256.0M+25.4%	$204.2M+193.9%	$69.5M+78.4%	$39.0M+9.4%	$35.6M+86.4%	$19.1M+130.9%	$8.3M+70.1%	$4.9M+109.6%	$2.3M+207.7%	$754K
Stock-Based Compensation	N/A	$80.4M-44.9%	$146.0M-27.6%	$201.6M-7.5%	$217.9M-28.0%	$302.6M-36.4%	$475.5M+612.9%	$66.7M+52.4%	$43.8M+43.0%	$30.6M+296.2%	$7.7M+151.2%	$3.1M+476.9%	$533K+78.9%	$298K
Capital Expenditures	$7.5M	$8.9M-17.6%	$10.8M-5.9%	$11.5M-30.4%	$16.5M+93.1%	$8.5M+112.1%	$4.0M+14.6%	$3.5M-12.5%	$4.0M+52.3%	$2.6M+24.9%	$2.1M-66.4%	$6.3M+487.0%	$1.1M+424.0%	$204K
Free Cash Flow	$253.7M	$285.5M+0.9%	$282.9M-16.4%	$338.6M+95.9%	$172.8M-6.8%	$185.5M+422.3%	-$57.5M-318.3%	$26.4M+397.1%	-$8.9M+76.1%	-$37.1M+31.3%	-$54.0M-1.0%	-$53.5M-330.1%	-$12.4M-98.6%	-$6.3M
Investing Cash Flow	-$161.2M	-$266.0M-114.4%	-$124.1M+20.7%	-$156.3M+6.8%	-$167.7M-129.8%	-$73.0M+87.7%	-$591.0M-2462.7%	$25.0M+109.7%	-$257.5M+42.6%	-$448.4M-1814.9%	$26.1M+124.2%	-$108.2M	N/A	N/A
Financing Cash Flow	-$4.1M	-$551.7M-6736.8%	$8.3M-23.4%	$10.9M+67.1%	$6.5M-84.1%	$40.9M-95.2%	$859.1M+2348.1%	$35.1M-94.6%	$645.6M+35.8%	$475.4M+2199.2%	$20.7M-87.4%	$164.0M	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$368K+418.3%	$71K

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$64.7M-29.3%	$9.5M-40.2%	$87.7M+2.1%	$99.3M-9.9%	$91.4M+3.1%	$15.9M+78.5%	$85.9M-34.0%	$110.2M+4.3%
Stock-Based Compensation	$9.3M-58.4%	$14.6M-41.9%	N/A	$17.0M-50.1%	$22.3M-46.9%	$25.2M-40.5%	N/A	$34.0M-35.7%
Capital Expenditures	$928K-26.8%	$1.7M-39.1%	$2.6M-57.3%	$2.3M+42.8%	$1.3M-33.7%	$2.7M+137.2%	$6.1M+336.8%	$1.6M-72.4%
Free Cash Flow	$63.7M-29.3%	$7.9M-40.5%	$85.1M+6.7%	$97.0M-10.7%	$90.2M+3.9%	$13.2M+69.8%	$79.8M-38.0%	$108.6M+8.8%
Investing Cash Flow	-$41.6M+30.3%	-$36.5M+70.4%	-$34.3M-15.8%	-$48.7M-56.4%	-$59.7M-115.1%	-$123.3M-247.1%	-$29.6M+18.8%	-$31.1M+17.3%
Financing Cash Flow	$875K+100.2%	-$2.4M-418.5%	$1.1M-46.4%	-$3.6M-614.6%	-$549.9M-14552.9%	$769K-56.1%	$2.1M+215.9%	$698K-86.2%

Not reported in any period shown, so not listed: Depreciation & Amortization, Dividends Paid, Share Buybacks.

TDOC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

TDOC quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Gross Margin	69.5%-1.3pp	70.8%0.0pp	70.8%+1.7pp	69.1%+1.1pp	68.0%+3.7pp	64.3%-2.4pp	66.7%-2.5pp	69.2%-4.4pp	73.6%-0.5pp	74.0%+1.2pp	72.8%-4.4pp	77.2%-1.8pp	79.0%
Operating Margin	-10.4%+29.3pp	-39.7%-30.2pp	-9.6%	-567.3%	-13.1%+33.2pp	-46.3%-31.8pp	-14.5%+2.4pp	-17.0%+15.4pp	-32.3%+18.6pp	-50.9%+21.2pp	-72.1%-37.3pp	-34.8%-5.3pp	-29.5%
Net Margin	-7.9%+31.1pp	-39.0%-30.5pp	-8.5%	-567.5%	-21.1%+23.3pp	-44.4%-26.5pp	-17.9%+5.4pp	-23.2%+22.5pp	-45.8%+14.5pp	-60.3%+14.7pp	-75.0%-35.8pp	-39.1%-8.9pp	-30.2%
Return on Equity	-14.5%+52.7pp	-67.2%-57.7pp	-9.5%+582.4pp	-591.9%-589.2pp	-2.7%+0.4pp	-3.0%+6.7pp	-9.8%-0.2pp	-9.6%+9.5pp	-19.1%+13.0pp	-32.1%+0.3pp	-32.5%	N/A	N/A
Return on Assets	-7.0%+21.5pp	-28.5%-23.5pp	-5.0%+309.3pp	-314.4%-311.9pp	-2.4%+0.3pp	-2.7%+3.4pp	-6.2%+0.2pp	-6.3%+6.6pp	-13.0%+11.5pp	-24.4%+0.8pp	-25.3%-6.7pp	-18.6%	N/A
Current Ratio	2.77+1.0x	1.77-1.8x	3.54+0.2x	3.29-0.4x	3.70+0.5x	3.19-3.3x	6.52-2.0x	8.53+4.7x	3.87-0.1x	3.93-4.5x	8.43+3.1x	5.28	N/A
Debt-to-Equity	1.06-0.3x	1.36+0.5x	0.890.0x	0.88+0.8x	0.110.0x	0.12-0.5x	0.58+0.1x	0.510.0x	0.47+0.3x	0.180.0x	0.14	N/A	N/A
Asset Turnover	0.89+0.2x	0.73+0.1x	0.590.0x	0.55+0.4x	0.11+0.1x	0.06-0.3x	0.35+0.1x	0.270.0x	0.28-0.1x	0.41+0.1x	0.34-0.1x	0.47	N/A
FCF Margin	11.3%+0.3pp	11.0%-2.0pp	13.0%+5.8pp	7.2%-1.9pp	9.1%+14.4pp	-5.3%-10.0pp	4.8%+6.9pp	-2.1%+13.8pp	-15.9%+27.9pp	-43.8%+25.2pp	-69.1%-40.5pp	-28.5%+2.9pp	-31.4%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	68.6%-1.3pp	67.8%-0.9pp	69.3%-1.2pp	70.1%-1.8pp	69.8%-0.9pp	68.7%-1.2pp	70.5%-0.2pp	71.9%+0.1pp
Operating Margin	-6.1%+2.5pp	-10.1%+9.1pp	-5.6%+1.9pp	-8.3%-1.4pp	-8.6%	-19.2%-5.7pp	-7.5%-2.2pp	-6.9%+2.9pp
Net Margin	-6.4%-1.2pp	-10.4%+4.4pp	-3.9%+3.6pp	-7.9%-2.7pp	-5.2%	-14.8%-2.1pp	-7.6%-3.2pp	-5.2%+3.4pp
Return on Equity	-3.0%-0.7pp	-4.8%+1.7pp	-1.8%+1.4pp	-3.6%-1.3pp	-2.3%+53.5pp	-6.5%-2.9pp	-3.2%-2.0pp	-2.2%+0.3pp
Return on Assets	-1.4%-0.3pp	-2.3%+0.4pp	-0.9%+0.5pp	-1.7%-0.8pp	-1.1%+22.6pp	-2.7%-0.8pp	-1.4%-0.7pp	-0.9%+0.4pp
Current Ratio	0.83-1.8x	2.80+1.1x	2.77+1.0x	2.70+1.0x	2.67+1.0x	1.68-2.1x	1.77-1.8x	1.73-1.7x
Debt-to-Equity	1.11+0.1x	1.10-0.3x	1.06-0.3x	1.07-0.3x	1.03-0.3x	1.41+0.5x	1.36+0.5x	1.34+0.5x
Asset Turnover	0.220.0x	0.220.0x	0.220.0x	0.220.0x	0.220.0x	0.180.0x	0.180.0x	0.180.0x
FCF Margin	10.5%-3.8pp	1.3%-0.8pp	13.3%+0.8pp	15.5%-1.5pp	14.3%+0.8pp	2.1%+0.9pp	12.4%-7.0pp	17.0%+1.8pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Teladoc Health, Inc. TDOC	FY2025	$2.5B	-$200.3M	-7.9%	$1.1B	41/100
GoodRx Holdings, Inc. GDRX	FY2025	$796.9M	$30.4M	3.8%	$1.2B	56/100
Schrodinger, Inc. SDGR	FY2025	$255.9M	-$103.3M	-40.4%	$1.9B	60/100
Omnicell Inc OMCL	FY2025	$1.2B	$2.1M	0.2%	$1.7B	42/100
Phreesia, Inc. PHR	FY2026	$480.6M	$2.3M	0.5%	$667.3M	45/100
Certara, Inc. CERT	FY2025	$418.8M	-$1.6M	-0.4%	$1.5B	51/100

Where Teladoc Health, Inc. Ranks

Frequently Asked Questions

What is Teladoc Health, Inc.'s annual revenue?

Teladoc Health, Inc. (TDOC) reported $2.5B in total revenue for fiscal year 2025. This represents a -1.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Teladoc Health, Inc.'s revenue growing?

Teladoc Health, Inc. (TDOC) revenue declined by 1.5% year-over-year, from $2.6B to $2.5B in fiscal year 2025.

Is Teladoc Health, Inc. profitable?

No, Teladoc Health, Inc. (TDOC) reported a net income of -$200.3M in fiscal year 2025, with a net profit margin of -7.9%.

What is Teladoc Health, Inc.'s gross margin?

Teladoc Health, Inc. (TDOC) had a gross margin of 69.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Teladoc Health, Inc.'s operating margin?

Teladoc Health, Inc. (TDOC) had an operating margin of -10.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Teladoc Health, Inc.'s net profit margin?

Teladoc Health, Inc. (TDOC) had a net profit margin of -7.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Teladoc Health, Inc.'s return on equity (ROE)?

Teladoc Health, Inc. (TDOC) has a return on equity of -14.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Teladoc Health, Inc.'s free cash flow?

Teladoc Health, Inc. (TDOC) generated $285.5M in free cash flow during fiscal year 2025. This represents a 0.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Teladoc Health, Inc.'s operating cash flow?

Teladoc Health, Inc. (TDOC) generated $294.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Teladoc Health, Inc.'s total assets?

Teladoc Health, Inc. (TDOC) had $2.9B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Teladoc Health, Inc.'s capital expenditures?

Teladoc Health, Inc. (TDOC) invested $8.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Teladoc Health, Inc. spend on research and development?

Teladoc Health, Inc. (TDOC) invested $277.9M in research and development during fiscal year 2025.

How many shares does Teladoc Health, Inc. have outstanding?

Teladoc Health, Inc. (TDOC) had 178M shares outstanding as of fiscal year 2025.

What is Teladoc Health, Inc.'s current ratio?

Teladoc Health, Inc. (TDOC) had a current ratio of 2.77 as of fiscal year 2025, which is generally considered healthy.

What is Teladoc Health, Inc.'s debt-to-equity ratio?

Teladoc Health, Inc. (TDOC) had a debt-to-equity ratio of 1.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Teladoc Health, Inc.'s return on assets (ROA)?

Teladoc Health, Inc. (TDOC) had a return on assets of -7.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Teladoc Health, Inc.'s P/E ratio?

Teladoc Health, Inc. (TDOC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.1B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Teladoc Health, Inc.'s price-to-sales ratio?

Teladoc Health, Inc. (TDOC) trades at 0.4x sales, its market capitalization divided by revenue of $2.5B revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.1B as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Teladoc Health, Inc.'s Altman Z-Score?

Teladoc Health, Inc. (TDOC) has an Altman Z-Score of -6.72, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Teladoc Health, Inc.'s Piotroski F-Score?

Teladoc Health, Inc. (TDOC) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Teladoc Health, Inc.'s earnings high quality?

Teladoc Health, Inc. (TDOC) reported a net loss of $200.3M while generating $294.4M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Teladoc Health, Inc. cover its interest payments?

Teladoc Health, Inc. (TDOC) reported an operating loss of $263.0M against $19.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Teladoc Health, Inc.?

Teladoc Health, Inc. (TDOC) scores 41 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.